Global Search | Novartis

Hide Filters

Showing 2716 results

Press Release / Oct 31, 2023

FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as early as Week 21 As the only IL-17A inhibitor…
Key Release / Nov 28, 2023

Novartis upgrades mid-term sales growth guidance, showcases its differentiated innovative medicines strategy and robust pipeline at R&D Day

Ad hoc announcement pursuant to Art. 53 LR ‘Pure-play’ innovative medicines strategy focused on four therapeutic areas and five technology platforms, which offer potential for consistent…
Press Release / Nov 09, 2023

Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2

In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria…
Press Release / Oct 23, 2023

Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting

Phase III PSMAfore trial with Pluvicto™ met its primary endpoint of radiographic progression-free survival (rPFS) with a HR of 0.411; Pluvicto more than doubled median rPFS to 12.0 months per updated…
Key Release / Oct 24, 2023

Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance

Ad hoc announcement pursuant to Art. 53 LR Transformation into a “pure-play” innovative medicines business is complete, with the spin-off of Sandoz; commentary below is on continuing…
Key Release / Oct 24, 2023

Novartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023

Annonce événementielle au sens de l’art. 53 RC Le spin-off de Sandoz parachève la spécialisation d’Innovative Medicines dans les médicaments innovants le commentaire ci-dessous concerne les…
Press Release / Oct 26, 2023

Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers

US FDA has classified drug shortage status as resolved1 Novartis capacity to produce Pluvicto will continue to grow with anticipated expansions to the manufacturing network in the US and globally…
Press Release / Sep 29, 2023

Novartis completes divestment of ‘front of eye’ ophthalmology assets

Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic…
Press Release / Sep 25, 2023

Novartis confirms Sandoz Spin-off for October 4, 2023

Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade…
Key Release / Oct 30, 2023

Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Ad hoc announcement pursuant to Art. 53 LR Phase III ALIGN study met its primary endpoint, demonstrating superiority of atrasentan vs. placebo in proteinuria reduction at 36-week interim analysis1;…